Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics

Launched by CANADIAN CANCER TRIALS GROUP · Oct 4, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes, is focused on studying how different treatments for cancer, specifically immunotherapy, work in patients with carcinoma (a type of cancer). The researchers want to collect fresh tumor samples and blood from participants to better understand how these treatments affect the body and to create a bank of samples for future research. This information could help doctors predict which treatments might work best for different patients.

To be eligible for this study, participants should be between the ages of 65 and 74 and must be willing to provide blood and tumor samples. This trial has specific groups based on patients' treatment stages: one group includes those starting immunotherapy, while the other includes those who have already received treatment. Participants can expect to contribute valuable information that could improve cancer care for others in the future. It's important to note that the trial is not yet recruiting participants, so there will be more information available as it progresses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willingness to submit a blood sample for buffy-coat and at least one tumour biospecimen.
• * CAN-PREDICT-IO subgroup:
• • Provision of pre-treatment fresh tumour biopsy/resection tumour tissue for patients who will receive IO treatment, in a specified list of IO therapeutic trials currently active in CCTG.
• • OR
• * CAN-PIVOT subgroup:
• • Provision of on-treatment or at-progression fresh tumour biopsy/resection tumour tissue for patients who have received IO treatment, in a specified list of IO therapeutic trials currently active in CCTG.
• • There are 2 CAN-PIVOT subgroups: Primary resistance is defined as disease progression evident in initial on-treatment imaging or disease stability lasting less than six months. Acquired resistance, on the other hand, manifests as disease progression subsequent to an initial partial or complete response or after a period of disease stability lasting six months or more. Patients on adjuvant treatment, wit no evidence of disease (NED) by radiological assessment who develop disease (local recurrence or metastases) after or while on immunotherapy are included.
• • Archived formalin fixed paraffin embedded (FFPE) blocks or slides would only be collected from patients who met CAN-IMPACT-IO study criteria and underwent fresh tumour biopsy/resection following consent but had a tumour specimen deemed insufficient for WGTS. The FFPE sample may be used to provide an alternate source of tumour tissue for WGTS in such cases. Where local centre regulations prohibit submission of blocks of tumour tissue, a predetermined number of unstained slides of representative tumour tissue may substitute the tumour block.
• • Participant consent for the CAN-IMPACT-IO study must be appropriately obtained in accordance with applicable local and regulatory requirements.